Literature DB >> 19443597

Comparison of 18F-FDG and PiB PET in cognitive impairment.

Val J Lowe1, Bradley J Kemp, Clifford R Jack, Matthew Senjem, Stephen Weigand, Maria Shiung, Glenn Smith, David Knopman, Bradley Boeve, Brian Mullan, Ronald C Petersen.   

Abstract

UNLABELLED: The purpose of this study was to compare the diagnostic accuracy of glucose metabolism and amyloid deposition as demonstrated by (18)F-FDG and Pittsburg Compound B (PiB) PET to evaluate subjects with cognitive impairment.
METHODS: Subjects were selected from existing participants in the Mayo Alzheimer's Disease Research Center or Alzheimer's Disease Patient Registry programs. A total of 20 healthy controls and 17 amnestic mild cognitive impairment (aMCI), 6 nonamnestic mild cognitive impairment (naMCI), and 13 Alzheimer disease (AD) subjects were imaged with both PiB and (18)F-FDG PET between March 2006 and August 2007. Global measures for PiB and (18)F-FDG PET uptake, normalized to cerebellum for PiB and pons for (18)F-FDG, were compared. Partial-volume correction, standardized uptake value (SUV), and cortical ratio methods of image analysis were also evaluated in an attempt to optimize the analysis for each test.
RESULTS: Significant discrimination (P < 0.05) between controls and AD, naMCI and aMCI, naMCI and AD, and aMCI and AD by PiB PET measurements was observed. The paired groupwise comparisons of the global measures demonstrated that PiB PET versus (18)F-FDG PET showed similar significant group separation, with only PiB showing significant separation of naMCI and aMCI subjects.
CONCLUSION: PiB PET and (18)F-FDG PET have similar diagnostic accuracy in early cognitive impairment. However, significantly better group discrimination in naMCI and aMCI subjects by PiB, compared with (18)F-FDG, was seen and may suggest early amyloid deposition before cerebral metabolic disruption in this group.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19443597      PMCID: PMC2886669          DOI: 10.2967/jnumed.108.058529

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  39 in total

1.  Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET.

Authors:  Alexander Drzezga; Timo Grimmer; Matthias Riemenschneider; Nicola Lautenschlager; Hartwig Siebner; Panagiotis Alexopoulus; Satoshi Minoshima; Markus Schwaiger; Alexander Kurz
Journal:  J Nucl Med       Date:  2005-10       Impact factor: 10.057

2.  Mayo's older Americans normative studies: category fluency norms.

Authors:  J A Lucas; R J Ivnik; G E Smith; D L Bohac; E G Tangalos; N R Graff-Radford; R C Petersen
Journal:  J Clin Exp Neuropsychol       Date:  1998-04       Impact factor: 2.475

3.  Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis.

Authors:  L Mosconi; W-H Tsui; S De Santi; J Li; H Rusinek; A Convit; Y Li; Madhu Boppana; M J de Leon
Journal:  Neurology       Date:  2005-06-14       Impact factor: 9.910

4.  The prevalence of amyloid (A4) protein deposits within the cerebral and cerebellar cortex in Down's syndrome and Alzheimer's disease.

Authors:  D M Mann; D Jones; D Prinja; M S Purkiss
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

5.  A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease.

Authors:  Mark H Tuszynski; Leon Thal; Mary Pay; David P Salmon; Hoi Sang U; Roy Bakay; Piyush Patel; Armin Blesch; H Lee Vahlsing; Gilbert Ho; Gang Tong; Steven G Potkin; James Fallon; Lawrence Hansen; Elliott J Mufson; Jeffrey H Kordower; Christine Gall; James Conner
Journal:  Nat Med       Date:  2005-04-24       Impact factor: 53.440

6.  Efficient radiosynthesis of carbon-11 labelled uncharged Thioflavin T derivatives using [11C]methyl triflate for beta-amyloid imaging in Alzheimer's Disease with PET.

Authors:  C Solbach; M Uebele; G Reischl; H-J Machulla
Journal:  Appl Radiat Isot       Date:  2005-04       Impact factor: 1.513

7.  Mild cognitive impairment in different functional domains and incident Alzheimer's disease.

Authors:  N T Aggarwal; R S Wilson; T L Beck; J L Bienias; D A Bennett
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-11       Impact factor: 10.154

8.  Characteristics of familial Alzheimer's disease in nine kindreds of Volga German ancestry.

Authors:  T D Bird; T H Lampe; E J Nemens; S M Sumi; D Nochlin; G D Schellenberg; E M Wijsman
Journal:  Prog Clin Biol Res       Date:  1989

Review 9.  Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.

Authors:  Lisa Mosconi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-04       Impact factor: 9.236

10.  MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET.

Authors:  L Mosconi; D Perani; S Sorbi; K Herholz; B Nacmias; V Holthoff; E Salmon; J-C Baron; M T R De Cristofaro; A Padovani; B Borroni; M Franceschi; L Bracco; A Pupi
Journal:  Neurology       Date:  2004-12-28       Impact factor: 9.910

View more
  106 in total

Review 1.  Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia.

Authors:  William E Klunk
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

Review 2.  Neuroimaging in psychiatric disorders.

Authors:  Joseph C Masdeu
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

3.  Shapes of the trajectories of 5 major biomarkers of Alzheimer disease.

Authors:  Clifford R Jack; Prashanthi Vemuri; Heather J Wiste; Stephen D Weigand; Timothy G Lesnick; Val Lowe; Kejal Kantarci; Matt A Bernstein; Matthew L Senjem; Jeffrey L Gunter; Bradley F Boeve; John Q Trojanowski; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; David S Knopman
Journal:  Arch Neurol       Date:  2012-07

4.  Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls.

Authors:  D P Devanand; Arthur Mikhno; Gregory H Pelton; Katrina Cuasay; Gnanavalli Pradhaban; J S Dileep Kumar; Neil Upton; Robert Lai; Roger N Gunn; V Libri; Xinhua Liu; Ronald van Heertum; J John Mann; Ramin V Parsey
Journal:  J Geriatr Psychiatry Neurol       Date:  2010-04-29       Impact factor: 2.680

Review 5.  FDG-PET for early assessment of Alzheimer's disease: isn't the evidence base large enough?

Authors:  Giovanni Lucignani; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08       Impact factor: 9.236

6.  Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort.

Authors:  Jeffrey L Dage; Alexandra M V Wennberg; David C Airey; Clinton E Hagen; David S Knopman; Mary M Machulda; Rosebud O Roberts; Clifford R Jack; Ronald C Petersen; Michelle M Mielke
Journal:  Alzheimers Dement       Date:  2016-07-18       Impact factor: 21.566

7.  Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies.

Authors:  Ing-Tsung Hsiao; Chin-Chang Huang; Chia-Ju Hsieh; Wen-Chun Hsu; Shiaw-Pyng Wey; Tzu-Chen Yen; Mei-Ping Kung; Kun-Ju Lin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-01-21       Impact factor: 9.236

8.  Cognitive impairment in lacunar strokes: the SPS3 trial.

Authors:  Claudia Jacova; Lesly A Pearce; Raymond Costello; Leslie A McClure; Stephen L Holliday; Robert G Hart; Oscar R Benavente
Journal:  Ann Neurol       Date:  2012-09       Impact factor: 10.422

9.  Partial volume correction in quantitative amyloid imaging.

Authors:  Yi Su; Tyler M Blazey; Abraham Z Snyder; Marcus E Raichle; Daniel S Marcus; Beau M Ances; Randall J Bateman; Nigel J Cairns; Patricia Aldea; Lisa Cash; Jon J Christensen; Karl Friedrichsen; Russ C Hornbeck; Angela M Farrar; Christopher J Owen; Richard Mayeux; Adam M Brickman; William Klunk; Julie C Price; Paul M Thompson; Bernadino Ghetti; Andrew J Saykin; Reisa A Sperling; Keith A Johnson; Peter R Schofield; Virginia Buckles; John C Morris; Tammie L S Benzinger
Journal:  Neuroimage       Date:  2014-12-05       Impact factor: 6.556

10.  Multi-Channel neurodegenerative pattern analysis and its application in Alzheimer's disease characterization.

Authors:  Sidong Liu; Weidong Cai; Lingfeng Wen; David Dagan Feng; Sonia Pujol; Ron Kikinis; Michael J Fulham; Stefan Eberl
Journal:  Comput Med Imaging Graph       Date:  2014-05-14       Impact factor: 4.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.